Originally posted here:
Originally posted here:
Prophecy Market Insights has recently published a Stem Cell Banking report which represents the latest industry data and future trends, allowing users to recognize the products and driving revenue growth and profitability of the market.
The report offers a broad analysis of key segments, key drivers, regions, and leading market players. The report contains an analysis of different geographical areas and presents a competitive scenario to promote leading market players, new entrants, and investors determine emerging economies. The key highlights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the Stem Cell Banking market.
Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/281
Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.
The Stem Cell Banking report begins with a brief introduction which contains a market overview of the industry followed by its market size and research scope. Further, the report provides an overview of market segmentation, for example- type, application, and region. The drivers, restraints, and opportunities for the market are also mentioned, along with current policies and trends in the industry. The Stem Cell Banking market also covers PEST analysis for the market. Thisanalysisprovides information based on four external factors (political, economic, social and technological) in relation to your business situation. Basically, it helps to understand how these factorswillaffect the performance and activities of your business in the long-term. The report describes the growth rate of each segment in-depth with the help of charts and tables. Moreover, various regions related to the growth of the Stem Cell Banking market are analyzed in the report. These regions include North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
Stem Cell Banking market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry. In this research report, there is an accurate analysis of the current and upcoming opportunities in the market by explaining the fastest and largest growing segments across regions. The survey report includes vast investigation of the geographical scene of the Stem Cell Banking market, which is manifestly arranged into the localities
Australia, New Zealand, Rest of Asia-Pacific
The study presents the performance of each player active in the Stem Cell Banking market. It also provides a summary and highlights the current advancements of each player in the market along with its SWOT analysis. The information provided in the research report is a great source for study investors and stakeholders interested in the market. In addition, the report offers insights on buyers, suppliers, and merchants in the market. There is a comprehensive analysis of consumption, market share, and growth rate of each application is offered for the historic period.
Stem Cell BankingMarket Key Players:
Cryo-cell International, Inc., Stem Cyte, Inc., ViaCord, Inc., Cord Blood Registry , Inc., SmartCells, Inc., LifeCell International Pvt.Ltd, Cryoviva Biotech Pvt. Ltd., Cryo StemcelPrivate Limited, Reliance Life Sciences Private Limited, and Trascell Biolife Pvt. Ltd.
Some important questions answered in Stem Cell Banking Market Report are:
Mr. Alex (Sales Manager)
Prophecy Market Insights
Phone: +1 860 531 2701
VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/
Go here to see the original:
New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Stem Cell Banking Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Stem Cell Banking market.
The research study includes the latest updates about the COVID-19 impact on the Stem Cell Banking sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.
Leading Stem Cell Banking manufacturers/companies operating at both regional and global levels:
The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.
The Stem Cell Banking market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.
The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Stem Cell Banking sector and can help companies in deciphering the optimum business move to reach their desired business goals.
In Market Segmentation by Types of Stem Cell Banking, the report covers-
In Market Segmentation by Applications of the Stem Cell Banking, the report covers the following uses-
To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=23773&utm_source=3WN&utm_medium=003
The Stem Cell Banking market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Stem Cell Banking market.
This study analyzes the growth of Stem Cell Banking based on the present, past and futuristic data and will render complete information about the Stem Cell Banking industry to the market-leading industry players that will guide the direction of the Stem Cell Banking market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.
The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Stem Cell Banking market. Additionally, it includes a share of each segment of the Stem Cell Banking market, giving methodical information about types and applications of the market.
Reasons for Buying Stem Cell Banking Market Report
This report gives a forward-looking prospect of various factors driving or restraining market growth.
It renders an in-depth analysis for changing competitive dynamics.
It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.
It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.
It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Stem Cell Banking market.
This report helps the readers understand key product segments and their future.
Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Banking-Market/?utm_source=3WN&utm_medium=003
In the end, the Stem Cell Banking market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.
To summarize, the Stem Cell Banking market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.
Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Mr. Edwyne Fernandes
US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768
See the rest here:
Cell Banking Outsourcing Market
IndustryGrowthInsights, 10-07-2020: The research report on the Cell Banking Outsourcing Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.
Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.
Get a PDF Copy of the Sample Report for Free @ https://industrygrowthinsights.com/request-sample/?reportId=172567
The Major Manufacturers Covered in this Report:SGS Life SciencesLonzaCCBCVcanbioAMAG PharmaceuticalsViaCordThermo FisherWuxi ApptecCordLifeEsperiteReliance Life SciencesLifecellCryo-CellToxikonGoodwin BiotechnologyTexcellCryo StemcellCell Banking Outsourcin
The Research Study Focuses on:
By Types:Stem Cell BankingNon-stem Cell BankingCell Banking Outsourcin
By Applications:Cell Bank StorageBank Characterization and TestingCell Bank Preparation
To get this report at incredible Discounts, visit @ https://industrygrowthinsights.com/ask-for-discount/?reportId=172567
The Cell Banking Outsourcing Market Report Consists of the Following Points:
Make an Inquiry of the Cell Banking Outsourcing Market Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=172567
In conclusion, the Cell Banking Outsourcing Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.
About IndustryGrowthInsights:IndustryGrowthInsights has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.
Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://industrygrowthinsights.com
See original here:
An inter-disciplinary team of researchers, funded by the University of Torontos Medicine by Design,hasgeneratedfunctional blood vessel cells found in the liver from stem cells a discovery thatoffersan opportunityto study the rolethe cellsplayin liver developmentand diseaseprogression, and which couldlead tonew therapies to treat hemophilia A.
Thestudy, titledGeneration of Functional Liver Sinusoidal Endothelial Cells from Human Pluripotent Stem Cell-Derived Venous Angioblasts,waspublished this week in Cell Stem Cell. Itrepresents a collaborative effort betweenbasic and clinical researchersat U of T and the University Health Network (UHN)with expertise in stem celland computationalbiology,human liver physiology and functionand liver transplantation.
It alsodraws onprevious Medicine by Design-funded research that led to the creationin 2018of the first single-cell map of the human liver.
By combining insights from developmental biology and liver anatomy with thecellatlasof the human liver,we were able to generateand validatefunctional human liver vasculature from stem cells, saysBlair Gage,apost-doctoral researcher at the McEwen Stem Cell Institute at UHNand lead author ofthestudy.Nowwe canmove forwardto use these liver endothelial cells tobetterunderstandtheir role in liver functionand to develop new therapies to treat disorderssuch ashemophilia A.
Theinterdisciplinary researchteam also includes:JeffLiu,research associate atU of TsDonnelly Centrefor Cellular andBiomolecularResearch;Brendan Innes, a PhD candidate at the Donnelly Centre and in thedepartment ofmolecular genetics in the Faculty of Medicine;Sonya MacParland, scientist in themulti-organ transplant program at theToronto General Hospital Research Institute andan assistant professor in U of Ts departments of immunology andlaboratory medicine and pathobiology; Ian McGilvray,senior scientist at themulti-organ transplant program at theToronto General Hospital Research Institute and a professorinU of Ts department of surgery;Gary Bader, professor at the Donnelly Centreandthedepartment ofmolecular genetics; andGordon Keller,director andsenior scientist at theMcEwen Stem Cell Institute at UHNandprofessor in U of Ts department of medical biophysics.
Researchersinthe Keller lab had the goal of generatinga functional liver vasculature cell type known as liver sinusoidal cells (LSECs)fromhuman pluripotent stem cells (hPSCs) cells that can self-renew and have the potential to turn into any other cell type in the human body. LSECs are essential for normal liver function and represent the main source of factor VIII,a blood-clotting protein that is missing or defective in patients with hemophilia A.
However, the teamhad todemonstratethatthecellstheyhadmadein the labhad thesamespecializedgenetic and functionalfeaturesasthose in thehuman liver.So they turned to the work of MacParland, Bader and McGilvray,whoin the first phase ofMedicine by Designs team projectfundingdescribed amolecularmap of the cell types in the adult liver.Thatresearchhascontributed totheHuman Cell Atlasan international effort to create comprehensive reference maps of all human cellsand last yearattracted follow-on funding from the Chan Zuckerberg Initiative.
This paper uses our human liver map as a guide to know if the cells beinggeneratedaretherightones through collaboration with Gary Baders group, says MacParland.The work really highlights thestrengthof MedicinebyDesignin bringingtogether researchers from multiple institutionstofocus on a common goal.
With Bader and Lius help, Keller lab researchers were able to use the MacParlandhuman livermapto show that thehPSC-derivedendothelialcellsthey had generatedshared manyof thefeatures found innormal liver vasculature. The Keller lab team then brought Innes on board toformat thedatafromthehPSC-derived LSECsfor the research communitytoeasilyexplorethe molecular profile of these cells.
This research was supported by Medicine by Design, which receives funding from the federal governmentsCanada First Research Excellence Fundand by theCanadian Institutes of Health Research.
The work continues in a current Medicine by Design-funded team projectled by Kellerthat aims to make other key liver cell types and put together the pieces to get functional tissueswith the goal of developing new cell-based therapies for liver-related diseases.That project is part ofanew $20-million round of team project fundingthat Medicine by Design announced late last year.
Medicine by Designbrings togetherinvestigatorsfromdifferent disciplinesatU of T and its affiliated hospitals to advance new discoveries in regenerative medicine and accelerate them toward clinical impact.Medicine by Designwill host ameeting of the Human Cell Atlass Development and Pediatric Atlasin July 2021in Toronto.
Go here to see the original:
In our new financial reality, our state and you as voters are faced with tough decisions. Come November, you will decide the fate of Californias stem cell institute. This decision has never been more important to the future of Californias health care, for the patients and their families, than it is now.
Californians overwhelmingly approved the states first stem cell initiative in 2004, with nearly 60% of the vote, and widespread support from patient advocacy organizations, labor, business and elected officials. The 2004 initiative established the California Institute for Regenerative Medicine (CIRM) to fund medical research and the development of new treatments and cures.
If Californians do not pass Proposition 14, vital lifesaving research will come to a halt.
CIRM funding has advanced research and therapy development for more than 75 different diseases and conditions, more than 90 clinical trials, more than 1,000 medical projects at 70 institutions across California and nearly 3,000 published medical discoveries. This investment has already saved and improved lives, including a high school student who was paralyzed in a diving accident and was able to regain function in his upper body and go on to college, a mother who went blind from a genetic disease has had some of her eyesight restored, two FDA-approved cancer treatments are already saving lives, and many more.
As funding for Californias stem cell research program has now run out, Californians have a critical opportunity to pass the 2020 stem cell initiative Proposition 14 to continue to advance lifesaving research and treatment development. Proposition 14 just recently qualified for the November ballot with early support from more than 65 patient advocacy organizations, the University of California and Nobel Prize winners.
If Californians do not pass Proposition 14, vital lifesaving research will come to a halt. Medical discoveries wont be able to progress to clinical trials, delaying lifesaving and life-changing treatments for cancer, diabetes, heart disease, Alzheimers, Parkinsons, infectious diseases like COVID-19 and more for years or decades.
Additionally, not passing Proposition 14 would eliminate a critical economic and jobs stimulus for our state.
Arguably, our state leaders are rightfully concerned about the state budget amid the current landscape. But as we enter a period of economic crisis, this bond measure will act as an economic recovery and jobs stimulus.
It is not a tax; it is a general obligation bond that will be repaid by the state, over decades, beginning in 2026.
Proposition 14 will increase the amount of state funds available to tackle other issues for the next 10 years by increasing state tax revenues through 2030 potentially providing more state revenue than the cost of bond payments during that time. To date, Californias stem cell research program has generated $10.7 billion in increased state economic activity and hundreds of millions in additional state revenues. Californias stem cell research program also creates tens of thousands of jobs at every level from lab technicians and maintenance workers to nurses and physicians.
Proposition 14 is exactly the kind of long-term investment we should make now to rebuild our economy. The initiative was specifically designed to be fiscally responsible. It is not a tax; it is a general obligation bond that will be repaid by the state, over decades, beginning in 2026 a full five years after its passage.
We cant afford not to fund Proposition 14.
Chronic diseases are the leading cause of death and the leading driver of annual health care spending and bankruptcies. In California alone, more than 30% of the states budget is spent on health care. With this cost rising every year, it is a growing strain on California families and our state budget.
If we hesitate to fund proper research to develop cures for chronic illnesses, our health care costs will financially drain California families, as well as our struggling state budget. Reducing the cost of treating just 6 of 80 major chronic diseases or injuries by 1-2% would pay for the Initiative twice over.
The decision you make in November will have lasting impacts on the state funds available to tackle priorities California needs to address now, and in the future, including housing, education, or the environment. Proposition 14 will generate additional revenue to help address these issues now, and potentially save California tens of billions for the future.
Proposition 14 will cost the state an average of less than $5 per person, per year about the cost of a bottle of aspirin. That is a small price to pay to potentially save millions of lives and tens of billions of dollars in health care costs in the coming decades. At the end of the day, Proposition 14 could save your life or the life of someone you love how can we afford not to make this investment?Editors Note: Bob Klein is chairman of Californians for Stem Cell Research, Treatments and Cures.
HIV, shown here budding from cell, remains stubbornly resistant to cure strategies because its DNA can lie silently in host chromosomes for years.
By Jon CohenJul. 7, 2020 , 9:00 AM
A 36-year-old man in Brazil has seemingly cleared an HIV infectionmaking him the proof of principle in humans of a novel drug strategy designed to flush the AIDS virus out of all of its reservoirs in the body. After receiving an especially aggressive combination of antiretroviral (ARV) drugs and nicotinamide (vitamin B3), the man, who asks to be referred to as the So Paulo Patient to protect his privacy, went off all HIV treatment in March 2019 and has not had the virus return to his blood.
The patients story is remarkable, says Steven Deeks, an HIV/AIDS clinician at the University of California, San Franciscowho was not involved with this study. But he and others, including the study leaders, caution that the success hasnt been long or definitive enough to label it a cure. Interesting anecdotes have long driven the HIV cure field, and they should be considered largely as hypothesis-generating observations that can simulate new areas of investigation, says Deeks, who also conducts HIV cure research.
Most people who suppress HIV with ARVs and later stop treatment see it come racing back to high levels within weeks. Not only did the So Paulo Patient not experience a rebound, but his HIV antibodies also dropped to extremely low levels, hinting at the possibility he may have cleared infected cells in the lymph nodes and gut.
Ricardo Diaz of the Federal University of So Paulo, the clinical investigator running the study, says he doesnt know whether the patient is cured. He has very little antigen, Diaz says, referring to HIV proteins that trigger the production of antibodies and other immune responses. But he notes his team has not sampled the mans lymph nodes or gut for the virus since he stopped treatment. Diaz discussed the patient today at a press conference for AIDS 2020, the 23rd International AIDS Conference taking place virtually this week, and he plans to present the study in full tomorrow.
Only two people are known to have been cured of their HIV infections:Timothy Ray Brown and a man who has asked to be referred to as the London Patient; both received bone marrow transplants as part of a treatment for cancers. The transplants cleared their infections and gave them new immune systems that resist infection with the virus. But bone marrow transplants are expensive, complicated interventions that can have serious side effects, making them an impractical cure for the 38 million people now living with the AIDS virus.
Other potential HIV cure cases have received intense media attention only to see the virus return after prolonged absences. Most soberingly, a baby in Mississippi who started ARVs shortly after birth stopped treatment at 18 months and was thought to be cured until the virus suddenly resurfaced more than 2 years later. Several adults who had bone marrow transplants and appeared to have been cured were not.
HIV has proven particularly difficult to eliminate because the virus weaves its genetic material into human chromosomes, where it can lie dormant, escaping the immune surveillance that typically eliminates foreign invaders. These silently infected cells may persist, perhaps indefinitely, because they have stem cell-like properties and can make clones of themselves. Researchers have come up with several strategies to flush reservoirs of cells that harbor latent HIV infections, but none have provedeffective.
To compare different reservoir-clearing strategies, Diaz and colleagues in 2015 recruited the So Paulo Patient and other individuals who had controlled their HIV infections with ARVs. The most aggressive approach, used in this man and four others, added two ARVs to the three they were already taking, in the hopethis would rout out any HIV that might have dodged the standard treatment. On top of this intensification, the study group received nicotinamide, which can, in theory, prod infected cells to wake up the latent virus. When those cells make new HIV, they either self-destruct or are vulnerable to immune attack.
After 48 weeks on this intensified schedule, the five trial participants returned to their regular three-drug regimen for 3 years, after which they stopped all treatment. Four saw the virus quickly return, but the So Paulo Patient has now gone 66 weeks without signs of being infected. Sensitive tests that detect viral genetic material did not find HIV in his blood. An even more sensitive test, which mixed his blood with cells that are susceptible to HIV infection, produced no newly infected cells.
Intriguingly, during the intensification period with nicotinamide, this man was the only one of the five who twice had the virus detected on standard blood tests. To Diaz, this suggests that latently infected cells had been roused, leading to blips of viral production. Im always trying to be a little bit the devils advocate, but in this case, Im optimistic, Diaz says. Maybe this strategy is not good for everybody because it only worked in one out of five here. But maybe it did get rid of virus. I dont know. I think this is a possibility.
Deeks says he does not know of any report, other than the two people cured by bone marrow transplants, of decreases in HIV antibody levels after stopping treatment. One large, outstanding question, he says, is whether the man indeed stopped taking his ARVs. I have not taken any HIV medication since March 30, 2019, the So Paulo Patient says. Diaz plans to confirm this by examining the mans blood for ARVs.
Another unknown is how soon the man started ARVs after becoming infected with HIV. Studies have shown that a small percentage of people who begin ARV treatment shortly after becoming infected have a better chance of controlling the virus for prolonged periods if they cease the drugs, presumably because they never built large reservoirs of infected cells. The So Paulo Patient started treatment 2 months after being diagnosed in October 2012. As with most people who become infected with HIV, he cannot say for certain when transmission occurred, but he suspects it was in June 2012. The only certainty is that he tested negative in 2010.
Its also unclear how nicotinamide would awaken silent infected cells. HIV DNA remains latent when it tightly spools around chromosome proteins known as histones. To make viral copies, it must unspool, and Diaz points to evidence that nicotinamide can trigger this unspooling in different ways.
Sharon Lewin, an HIV cure researcher who directs the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia, finds the antibody response intriguing. But she underscores it is not a convincing, controlled experiment. We need to move beyond case reports of HIV remission, Lewin says. I would be super excited to see long term remission in multiple participants in a clinical trial. This is what the field needs to really advance.
Originally posted here:
Newswise The key components of electrical connections between light receptors in the eye and the impact of these connections on the early steps of visual signal processing have been identified for the first time, according to research published today in Science Advances by The University of Texas Health Science Center at Houston (UTHealth).
To understand fully how the light receptors, called photoreceptors, impact the early stages of the process of vision, researchers have traditionally focused their attention on how two key sensory cells rods and cones convert elementary particles of light into electrical signals and how these signals are relayed to the brain through devoted circuits. Rods are used for night vision and cones are used for daytime and color vision. While it has been known for some time that electrical signals can spread between photoreceptors through cell connectors called gap junctions, the nature and function have remained poorly understood.
This research will lead to a better understanding of how the retina processes signals from the rods and the cones in the eyes, in particular under ambient lighting conditions when both photoreceptor types are active, such as at dawn and dusk. This knowledge is currently missing and may have to be taken into consideration when designing photoreceptor or retinal implants to restore vision, said Christophe P. Ribelayga, PhD, co-lead author of the study and associate professor and Bernice Weingarten Chair in the Ruiz Department of Ophthalmology & Visual Science at McGovern Medical School at UTHealth.
Co-lead author Steve Massey, PhD, is professor, Elizabeth Morford Chair, and research director in the Ruiz Department of Ophthalmology & Visual Science at McGovern Medical School at UTHealth.
The coupling or communication between rods and cones in the retina is critical for understanding how the visual signaling process works.
What the researchers discovered, to their surprise, is that rods do not directly communicate with other rods and cones seldom communicate directly with other cones. Instead, the majority of signaling happens through communication between rods and cones. Researchers identified a specific protein called connexin36 (Cx36) as the main component of rod/cone gap junctions.
We noted that every single rod has electrical access to a cone and that cone/cone gap junctions are very rare, Massey said. We estimated that more than 95% of all gap junctions between photoreceptors are rod/cone gap junctions; they have the largest volume and the largest conductance. So, rod/cone gap junctions dominate the network of photoreceptors both in size and number.
To help researchers better understand how the photoreceptor network is organized, they developed genetic mouse strains for the work that were bred to eliminate gap junctions in either rods or cones.
Our study has important implications, said Ribelayga. Our data position rod/cone gap junctions as the keystone of the photoreceptor network. The rod/cone gap junction is the entry of a rod pathway through which signals of rod origin can travel across the retina. We have thus generated mice that are essentially deficient for the entry of this pathway. In future experiments, we will use these animals to determine the functional importance of the rod/cone pathway in the retinal processing of rod signals and for vision.
In 2018, researchers in the Ruiz Department of Ophthalmology & Visual Science received more than $4 million in grants from the National Institutes of Healths National Eye Institute to study photoreceptor development, function, and electrical interactions. Ribelayga and Massey led the effort to lay out the architecture of the network of electrically coupled receptors, a critical step toward a better understanding of how photoreceptors encode light signals and how the retina processes these signals.
Additional UTHealth authors include Nange Jin, PhD; Zhijing Zhang, PhD; Joyce Keung, PhD; Munenori Ishibashi, PhD; Lian-Ming Tian; Iris Fahrenfort, PhD; Takae Kiyama, PhD; Chai-An Mao, PhD; David W. Marshak, PhD; Jiaqian Wu, PhD; Haichao Wei, PhD; and Yanan You, PhD. Marshak is with McGovern Medical Schools Department of Neurobiology and Anatomy; and Wu, Wei, and You are with the UTHealth Center for Stem Cell and Regenerative Medicine at the Brown Foundation Institute of Molecular Medicine.
Other authors include Sean B. Youn with Rice University; Eduardo Solessio, PhD; and Yumiko Umino, PhD, with the Center for Vision Research and SUNY Eye Institute at SUNY Upstate Medical University; and Friso Postma, PhD; and David L. Paul, PhD, with Harvard University.
See the rest here:
Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.
The global stem cell therapy market is categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.
Request For Report Sample:http://marketgrowthanalysis.com/reports/sample/217
Stem Cell Therapy Market, By Treatments:
Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy
Stem Cell Therapy Market, By End Users:
HospitalsAmbulatory Surgical Centers
Stem Cell Therapy Market, By Application:
OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System Disorders
Request For COVID-19 Analysis:http://marketgrowthanalysis.com/reports/enquiry/217
Stem Cell Therapy Market, By Geography:
North AmericaEuropeAsia PacificMiddle East & AfricaLatin America
In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.
Key Players in the Stem Cell Therapy Market are:
Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.
Request For Report TOC:http://marketgrowthanalysis.com/reports/toc/217
The rest is here:
Newswise Scientists focused on finding better treatments or cures for types 1 or 2 diabetes are painfully aware of current limitations, including having to use animal tissue in studies that often dont translate to human trials.
New research published June 29 in Nature Communications could help researchers overcome some of the biggest challenges of taking diabetes research from the lab to human trials and the clinic.
By using a technology first developed at the University of Miami Miller School of Medicine along with a Miller School patented approach to enhance the oxygenation of cultured tissues, researchers will likely be able to conduct real-time regeneration and development studies in the human pancreas.
The finding could lead to treatments that regenerate ones own pancreas without the need for transplantation, according to the studys senior author Juan Domnguez-Bendala, Ph.D., director of stem cell development for translational research and associate professor of Surgery at the Diabetes Research Institute, University of Miami Miller School of Medicine.
Dr. Bendala explained that in people who have type 1 diabetes, the bodys own immune system kills beta cells, or islet cells, in the pancreas that make insulin. Doctors have for years transplanted donor islet cells to replenish those cells.
But there are challenges to the approach. One is a scarcity of donors for organ transplantation. Another is when transplanting the islet cells is possible, the recipients body will likely reject the donor cells unless the recipient is immunosuppressed. Immunosuppression, alone, leads to complications.
The two pillars of our research are to replenish the islet cells that have been lost and then to stop autoimmunity, which is the underlying cause of the disease, Dr. Bendala said. We also are interested in using endogenous regeneration. We have found that there are pancreatic stem cells that we call progenitors because they already have committed to become part of the pancreatic tissue. Ultimately, we want to induce them to replicate and give rise to new insulin-producing cells within the patient, instead of transplanting beta cells from an external source.
Human pancreatic slices are very thin slices of the pancreas that keep together the organs natural architecture, including the much-needed islets.
The islets in these slices are surrounded by acinar cells, which make the digestive juices in the pancreas, and more importantly the ducts, where we have found the progenitor stem cells that can give rise to new beta cells, Dr. Bendala said. Thats why these slices are a very powerful tool to study the organ. Its as if you had a window into the living pancreas.
The problem when studying the regenerative process in human pancreatic slices has been that the tissue lasts only a couple of days before disintegrating and dying.
Dr. Bendala and colleagues determined that the main reason for cell death in the slices was a lack of oxygen. The pancreas is a very vascularized organ, and slicing it cuts off its blood supply.
Dr. Bendala and coauthor on the Nature Communications paper Ricardo Pastori, Ph.D., research professor of medicine, immunology, and microbiology and the director of the Molecular Biology Laboratory at the Diabetes Research Institute, circumvented the problem by placing human pancreatic slices in a culture device they invented that uses a perfluorocarbon (PFC) membrane.
PFC is a compound that is so rich in oxygen that you can breathe it in its liquid form, Dr. Bendala said. We have published on this device and shown that islets survive and function much better when we culture them on PFC. And when we differentiate stem cells into beta cells, the process occurs much more efficiently when you put them in PFC. It was no surprise that when we placed the human pancreatic slices into the PFC membrane that they survived and did much better than controls. We could keep them alive for about 2 weeks, some went as long as 3 weeks, and they were fully functional during that time.
Keeping human pancreatic slices alive for that long is a major breakthrough in diabetes research, especially in the area of islet cell regeneration, he said.
You need a model when you study regeneration. Traditionally we have used the mouse model, and, unfortunately what happens in mice in the lab often doesnt pan out in humans, Dr. Bendala said. This work is revolutionary because using these human pancreatic slices we can witness and monitor regeneration in a human model that resembles a real organ. That was not possible before because the tissue simply didnt live long enough.
The Miller School researchers also tested a molecule called BMP-7, which they have shown in previous studies to act as fuel to stem cells. They showed in this paper that BMP-7 can induce proliferation of pancreatic progenitors in human pancreatic slices.
When we added BMP-7 to human pancreatic slices, we could detect progenitor cells activating, proliferating and then giving rise to new beta cells. We could see that happening before our very eyes, he said.
The fact that the study also included tissue from human type 2 and type 1 diabetic patients makes it more much more likely that the research will facilitate progress to human clinical trials.
I took a step back when I saw this for the first time. This was a living human pancreatic slice from a patient who had passed 10 days ago, he said. I couldnt help but think, imagine if we had done this in the patient if he or she was still alive? Its really powerful.
Dr. Bendala sent PFC-based dishes at no cost to several other centers conducting diabetes research, so they could study the approach and potentially replicate the findings. In the meantime, Dr. Bendala and Miller School colleagues are screening molecules other than BMP-7 to see if they have potential to create new beta cells by inducing progenitors or by inducing the replication of pre-existing beta cells.
The goal is to have a therapy to present to the FDA to produce beta cells within a few years.
These technologies will greatly accelerate our ability to decide what is going to work in clinical trials, he said.